Glenn Sblendorio, Iveric Bio CEO

Eye-fo­cused Iver­ic Bio re­ports pos­i­tive PhI­II read­out as shares surge, FDA fil­ing planned

A biotech has claimed a sec­ond Phase III win, and that com­pa­ny is tak­ing its win all the way to the bank — and ul­ti­mate­ly the FDA.

New Jer­sey biotech Iver­ic Bio put out word of its pos­i­tive re­sults Tues­day, say­ing that the com­pa­ny’s drug can­di­date had met the pri­ma­ry end­point of the mean rate of growth (slope) in ge­o­graph­ic at­ro­phy over 12 months. The study en­rolled 448 pa­tients with GA, the most ad­vanced stage of dry AMD, al­so known as age-re­lat­ed mac­u­lar de­gen­er­a­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.